Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Short-term Investments (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Short-term Investments for 4 consecutive years, with $244.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments fell 40.0% to $244.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $244.0 million, a 40.0% decrease, with the full-year FY2025 number at $244.0 million, down 40.0% from a year prior.
  • Short-term Investments was $244.0 million for Q4 2025 at Day One Biopharmaceuticals, down from $408.3 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $439.7 million in Q1 2025 to a low of $47.6 million in Q1 2024.
  • A 4-year average of $253.9 million and a median of $253.6 million in 2022 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: plummeted 82.32% in 2024, then surged 824.57% in 2025.
  • Day One Biopharmaceuticals' Short-term Investments stood at $257.0 million in 2022, then plummeted by 47.25% to $135.6 million in 2023, then skyrocketed by 200.05% to $406.8 million in 2024, then plummeted by 40.0% to $244.0 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Short-term Investments are $244.0 million (Q4 2025), $408.3 million (Q3 2025), and $417.5 million (Q2 2025).